Every Form 4 that NeuroSense Therapeutics Ltd. Warrant (NRSNW) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow NRSNW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NRSNW filings page.
NeuroSense Therapeutics Ltd. Chief Financial Officer Or Eisenberg reported an open-market-style purchase of the company’s ordinary shares. On June 16, 2026, he acquired 250,000 ordinary shares at a price of $0.80 per share under a Securities Purchase Agreement dated April 28, 2026, executed as a private placement exempt from registration under Section 4(a)(2) of the Securities Act of 1933. Following this transaction, his direct holdings increased to 1,504,050 ordinary shares.
NeuroSense Therapeutics Ltd. Chief Executive Officer Ben-Noon Alon acquired 250,000 ordinary shares on June 16, 2026 at $0.80 per share. The purchase was made in a private placement under a Securities Purchase Agreement dated April 28, 2026, exempt from registration under Section 4(a)(2) of the Securities Act of 1933. Following this transaction, Alon directly holds 4,534,233 ordinary shares.
Eisenberg Or reported acquisition or exercise transactions in this Form 4 filing.
NeuroSense Therapeutics Ltd. Chief Financial Officer Eisenberg Or received a grant of 200,000 restricted Ordinary Shares as equity compensation. The shares were granted at $0.00 per share and will vest in equal quarterly installments over a two-year period starting on March 26, 2026, provided he continues to serve the company on each vesting date. Following this award, he directly holds 1,254,050 Ordinary Shares.
Russek-Blum Niva reported acquisition or exercise transactions in this Form 4 filing.
NeuroSense Therapeutics Ltd. reported that Chief Technology Officer Niva Russek-Blum received a grant of 200,000 Ordinary Shares. These are restricted shares awarded as compensation at a stated price of $0.00 per share, increasing her direct holdings to 467,953 Ordinary Shares after the grant.
The restricted shares vest in equal quarterly installments over a two-year period, starting from the grant date of March 26, 2026, and depend on her continued service with the company. Footnotes note that, to qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued under the company’s 2018 Share Incentive Plan must be registered in the name of a trustee.
Binder Hagit reported acquisition or exercise transactions in this Form 4 filing.
NeuroSense Therapeutics Ltd. granted General Manager Hagit Binder 200,000 Ordinary Shares as a share-based compensation award, recorded at a price of $0.0000 per share. Following this grant, Binder directly holds 521,806 Ordinary Shares.
The award consists of restricted shares that vest in equal quarterly installments over a two-year period starting on March 26, 2026, conditioned on Binder’s continued service with the company at each vesting date. To qualify for certain Israeli tax benefits under Section 102, the securities must be registered in the name of a trustee, but they are reported here as directly owned by Binder.